<DOC>
	<DOCNO>NCT02032745</DOCNO>
	<brief_summary>A genomic test develop predict chemo-sensitivity taxane-anthracycline-based chemotherapy neoadjuvant treatment . The primary aim study prospectively evaluate microarray-based , genomic test predictor axillary lymph node response . Also , determine whether probability achieve negative axillary node , sufficiently high patient whose breast cancer predict chemo-sensitive support omit axillary dissection .</brief_summary>
	<brief_title>Genomic Signatures Predict Treatment Response</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Clinical status lymph node must available Sonographical status lymph node must available Patients must consent documentation cancer treatment Histologic diagnosis invasive breast cancer , clinical stage T14 , M0 ( noninflammatory T4c ) Patients schedule neoadjuvant chemotherapy Treatment 3weekly FEC AC regimen ( 34 cycle ) follow 34 cycle q3 weekly docetaxel paclitaxel . Local HER2 status tumor biopsy must negative . The patient prior history invasive metastatic breast cancer . The patient prior excisional biopsy primary invasive breast cancer . The patient prior ipsilateral sentinel axillary lymph node biopsy breast cancer . The patient safely feasibly undergo biopsy primary tumor . The patient diagnosis Stage IV ( distant metastatic ) breast cancer . The patient proven HER2positive breast cancer , define pathology report amplification gene 3+ score immunohistochemical staining .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>